SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK
plc (the
'Company')
2026 Performance Share Plan Award and 2026 Performance
Measures
2026 Performance Share Plan Award
On 12 February 2026, the Company granted conditional share awards
to the Persons Discharging Managerial Responsibilities ('PDMRs')
and their Persons Closely Associated ('PCAs') listed below under
the GlaxoSmithKline 2017 Performance Share Plan ('the Plan'). The
Plan allows a performance-related opportunity in the form of
conditional awards to be granted to senior executives in the Group,
including the Executive Directors and other
PDMRs.
Under the terms of the Plan, conditional awards are granted over a
specific number of Ordinary Shares or American Depositary Shares
('ADS'), and the percentage of awards that ultimately vests is
dependent on the level of achievement against performance targets
set by the Remuneration Committee.
The performance period for the awards is the three financial years
from 1 January 2026 to 31 December 2028.
2026 Performance Measures
The awards are based on the following five measures:
|
Performance Measure
|
Proportion of
each award
|
|
Total Sales Growth
|
17.5%
|
|
Core Operating Profit Growth
|
17.5%
|
|
Pipeline Sustainability
|
17.5%
|
|
Responsible Business: Composite Scorecard
|
7.5%
|
|
Relative Total Shareholder Return (TSR)
|
40%
|
Total sales and Core operating profit growth
These targets were set following the Board's annual planning
process and consideration of analysts' consensus to ensure that
they are sufficiently stretching and support the Committee's aim to
incentivise and reward over performance.
|
|
Performance vs Target
|
Proportion Vesting
|
|
Below threshold
|
< 99% of Target
|
Nil
|
|
Threshold
|
99% of Target
|
20%: CEO
25%: CFO / All Others
|
|
Target
|
100% of Target
|
50%
|
|
|
103% of Target
|
75%
|
|
Maximum
|
105% of Target
|
100%
|
Pipeline Sustainability
The Pipeline Sustainability measure focuses on GSK's replenishment
of the pipeline and longer-term pipeline performance. For
inclusion, a Programme must be either a New Molecular Entity (NME),
or a new indication which adds £0.5 billion to Peak Year
Sales. Programmes approved and launched during the three-year
window will contribute to the total number of assets and to the
sales contribution. It is based on a matrixed assessment
of:
-
Pipeline sales contribution to GSK's long range forecast (LRF)
outlook. The target and vesting will each be based on 10-year net
risk adjusted sales forecast, e.g., the 2026-2028 target based on
the 2035 LRF and vesting based on the 2038 LRF, and
- the Number of Programmes in Phase 2 and 3 and Registration and
Approval.
This element of the PSP will only vest, either in full or in part,
if at the time of vesting the most recently governed and published
2031 Sales outlook remains at least £40
billion1.
At the end of the period a list of the Programmes added or removed
during the period will be disclosed. However, the pipeline sales
contributions in the 2035 and 2038 LRFs and the assessment matrix
will not be disclosed, as they are commercially sensitive. For the
achievement of Threshold performance for both the Pipeline Sales
contribution and the number of Programmes, the vesting proportions
shall be 20% for the CEO, and 25% for the CFO / All
Others.
Responsible Business: Composite scorecard
The Composite scorecard focuses on all the Responsible Business
metrics within the Responsible Business Performance Rating. The
rating is reported on in detail in each year's Annual Report with
the scorecard providing a balanced assessment of performance
against all our Responsible Business priorities.
Performance will be calculated by aggregating the annual
performance across all the individual annual metrics within the
rating for the 3 years of the PSP performance period.
|
Performance
|
Vesting Schedule
|
|
70% or more of all metrics are on track
|
100%
|
|
60% of all metrics are on track
|
75%
|
|
50% of all metrics are on track
|
50%
|
|
Less than 50% of all metrics are on track, but progress is being
made because at least 50% are either on track, or on track with
work to do (the 'threshold' vesting level)
|
20%: CEO
25%: CFO / All Others
|
|
Less than 50% of all metrics are either on track or on track with
work to do, the rest (i.e. more than 50%) are off
track
|
Nil
|
Relative TSR
Performance against our size-adjusted global biopharma peer group
of 13 companies will be assessed using a percentile vesting
approach. This compares GSK's actual TSR performance with that of
our peers.
The median TSR and the upper quintile TSR of the peers is
calculated excluding GSK's TSR. GSK's TSR is then compared against
the median and upper quintile TSR on an interpolated basis.
Threshold performance is at median, and maximum vesting (100%) is
achieved for upper quintile performance. Straight-line
interpolation determines vesting levels between median and upper
quintile.
|
TSR Performance
|
Vesting Schedule
|
|
Above upper quintile
|
100%
|
|
Upper quintile
|
100%
|
|
Between median and upper quintile
|
Straight-line interpolation
|
|
Median (threshold vesting)
|
20%: CEO
25%: CFO / All Others
|
|
Below median of peer group
|
Nil
|
1 See assumptions and basis of
preparation related to 2026 guidance, 2021-26 and 2031 Outlooks
within GSK's Full-year and fourth quarter 2025 results announcement
and GSK's cautionary statement below.
Notes
1.
To the extent that each element of a conditional award does not
vest at the end of the three-year performance period, it will
lapse.
2.
The PDMRs in the transaction notifications below were each granted
a conditional award under the terms of the GlaxoSmithKline 2017
Performance Share Plan. Awards granted are of Ordinary Shares or
ADS.
3.
Dividends will accrue on the conditional award of Ordinary Shares
or ADS during the performance period but will only vest to the
extent that the awards themselves vest at the end of the
performance period. These dividends are not included in the figures
below.
4. For
Executive Directors, the award is subject to an additional
holding period of two years (the 'Holding Period') from the normal
vesting date, i.e. five years in total. During the
Holding Period, the relevant Ordinary Shares or ADS would only be
forfeited in the event that the Executive Director was
terminated for cause, and the Ordinary Shares or ADS will continue
to carry rights to dividend equivalents.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Luke Miels
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
463,662
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Julie Brown
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
196,548
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Lynn Baxter
|
|
b)
|
Position/status
|
President, Europe
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
32,757
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mike Crichton
|
|
b)
|
Position/status
|
President, International
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
37,315
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
133,977
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mondher Mahjoubi
|
|
b)
|
Position/status
|
Chief Patient Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
37,906
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Maya Martinez-Davis
|
|
b)
|
Position/status
|
President, US
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADS')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
A conditional award of ADS under the Company's 2017 Performance
Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$58.49
|
53,433
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Nina Mojas
|
|
b)
|
Position/status
|
President, Global Product Strategy
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
38,291
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Shobie Ramakrishnan
|
|
b)
|
Position/status
|
Chief Digital and Technology Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADS')
ISIN: US37733W2044
|
|
b)
|
Nature
of the transaction
|
A conditional award of ADS under the Company's 2017 Performance
Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$58.49
|
44,313
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
David Redfern
|
|
b)
|
Position/status
|
President, Corporate Development
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
143,579
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Regis Simard
|
|
b)
|
Position/status
|
President, Global Supply Chain
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
150,453
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Phil Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
66,221
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Deborah Waterhouse
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
136,579
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Tony Wood
|
|
b)
|
Position/status
|
Chief Scientific Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.50
|
247,138
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Victoria Whyte
|
|
b)
|
Position/status
|
SVP & Company Secretary
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.41
|
11,800
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Neil Falkingham
|
|
b)
|
Position/status
|
PCA of Lynn Baxter (President, Europe)
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A conditional award of Ordinary Shares under the Company's 2017
Performance Share Plan
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.41
|
11,800
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q4 Results for 2025.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
16, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
